Lymphopenia in Multiple Sclerosis patients treated with Ocrelizumab is associated with an effect on CD8 T cells.
Lymphocyte subsets
Lymphocytes
Lymphopenia
Multiple Sclerosis
Ocrelizumab
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
22
01
2022
revised:
26
02
2022
accepted:
11
03
2022
pubmed:
20
3
2022
medline:
20
5
2022
entrez:
19
3
2022
Statut:
ppublish
Résumé
In the phase III, OPERA I and OPERA II, clinical trial lymphopenia was reported in 20.7% of relapsing-remitting multiple sclerosis (RRMS) patients taking Ocrelizumab (OCR). The objective of this study was to investigate the effect of OCR on lymphocyte subtypes in MS patients with and without lymphopenia. Retrospective study comparing lymphocyte subtypes in OCR-treated MS patients with low (G1) and normal (G2) absolute lymphocyte count (ALC) at the six-month follow-up (cut-off: 1000 × 10 One hundred sixty-seven patients were included (G1, n = 34; G2, n = 133). At the six-month follow-up, compared with baseline, in the whole population we observed a significant reduction in ALC (p<0.0001), CD19 (p<0.0001) and CD8 T (p<0.0288) lymphocytes. We also found and increase in CD4/CD8 ratio after six months of treatment (p = 0.0098). G1 showed a lower ALC than G2 at baseline. At six months, mean ALC was 896.41 ± 156.25 × 10 OCR decreases ALC. Among T cells, the treatment predominantly impacts CD8 cells. However, CD8 T cell decrease was more pronounced in patients with lymphopenia. Further studies are needed to establish the relationship between the effect of OCR on ALC and CD8 T cells and its potential implication in the early clinical response and risk for viral infections.
Sections du résumé
BACKGROUND
BACKGROUND
In the phase III, OPERA I and OPERA II, clinical trial lymphopenia was reported in 20.7% of relapsing-remitting multiple sclerosis (RRMS) patients taking Ocrelizumab (OCR).
OBJECTIVE
OBJECTIVE
The objective of this study was to investigate the effect of OCR on lymphocyte subtypes in MS patients with and without lymphopenia.
METHODS
METHODS
Retrospective study comparing lymphocyte subtypes in OCR-treated MS patients with low (G1) and normal (G2) absolute lymphocyte count (ALC) at the six-month follow-up (cut-off: 1000 × 10
RESULTS
RESULTS
One hundred sixty-seven patients were included (G1, n = 34; G2, n = 133). At the six-month follow-up, compared with baseline, in the whole population we observed a significant reduction in ALC (p<0.0001), CD19 (p<0.0001) and CD8 T (p<0.0288) lymphocytes. We also found and increase in CD4/CD8 ratio after six months of treatment (p = 0.0098). G1 showed a lower ALC than G2 at baseline. At six months, mean ALC was 896.41 ± 156.25 × 10
CONCLUSION
CONCLUSIONS
OCR decreases ALC. Among T cells, the treatment predominantly impacts CD8 cells. However, CD8 T cell decrease was more pronounced in patients with lymphopenia. Further studies are needed to establish the relationship between the effect of OCR on ALC and CD8 T cells and its potential implication in the early clinical response and risk for viral infections.
Identifiants
pubmed: 35305426
pii: S2211-0348(22)00255-3
doi: 10.1016/j.msard.2022.103740
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
ocrelizumab
A10SJL62JY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103740Informations de copyright
Copyright © 2022. Published by Elsevier B.V.